[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 717
Citations 0
Editorial
February 2014

Proximal Intracranial Arterial OcclusionsDoes the Natural History Justify Further Interventional Trials?

Author Affiliations
  • 1Stroke Division, Neurological Institute of New York, Columbia University Medical Center, New York, New York
JAMA Neurol. 2014;71(2):139-140. doi:10.1001/jamaneurol.2013.5370

Over the past 2 decades, the treatment of acute ischemic stroke has undergone significant changes. The National Institute of Neurological Disorders and Stroke tissue plasminogen activator study1 in 1995 followed by the third European Cooperative Acute Stroke Study (ECASS III)2 in 2008 heralded major breakthroughs in the hyperacute management of patients with ischemic stroke. Yet despite the promise of these landmark studies, the overall use of intravenous tissue plasminogen activator remained meager, reaching less than 5% of all stroke patients in the United States through 2006.3 Furthermore, for certain stroke subtypes, such as those with proximal intracranial arterial occlusions, the rate of recanalization remained low,4 resulting in poor outcomes when early recanalization was not achieved.5

First Page Preview View Large
First page PDF preview
First page PDF preview
×